Metabolic syndrome is a big risk factor for early dementia, and what you do makes a difference, study suggests
To be diagnosed with metabolic syndrome, a person must have three of the following conditions: a large waistline, high blood pressure, high blood sugar, high blood triglycerides, and low levels of high-density lipoprotein cholesterol, also known as HDL or 'good' cholesterol.
People who had metabolic syndrome, or a combination of those components, were 24% more likely to develop dementia at a young age, the data showed.
'The key takeaway (of the study) is that metabolic syndrome significantly increases the risk of developing young-onset dementia,' which is dementia before age 65, said principal study investigator Dr. Minwoo Lee, in an email. 'Our findings highlight the importance of managing metabolic health early to potentially prevent dementia and maintain brain health.'
The study analyzed data of nearly 2 million people from the Korean National Health Insurance Service who underwent health checkups. Researchers analyzed the markers of metabolic syndrome and who developed young-onset dementia between 2009 and the end of 2020, according to the study published Wednesday in the journal Neurology.
'Each component — such as elevated blood pressure, high blood sugar, obesity, abnormal cholesterol levels — is individually linked to higher dementia risk,' said Lee, assistant professor in the department of neurology at Hallym University Sacred Heart Hospital in South Korea.
The finding suggests an increased risk for much of the US population, as about 1 in 3 adults in the United States have metabolic syndrome, according to the National Heart, Lung, and Blood Institute.
'Dementia is among our most feared diseases, and developing dementia at an early age is even more worrisome,' said Dr. Richard Isaacson, a preventive neurologist and director of research at the Institute for Neurodegenerative Diseases in Boca Raton, Florida. He was not involved in the new study.
'People of all ages –– from the 20s, 30s, 40s, 50s and beyond –– should be empowered to make brain-healthy choices early on,' Isaacson said. 'I think this study gives us more evidence to suggest that these brain-healthy choices may lead to better brain outcomes over time.'
It is important to note that the study was observational, which means that researchers can't say that metabolic syndrome caused dementia, only that there was a correlation between the two, Isaacson said.
'I don't really think that vascular risk factors and metabolic syndrome causes Alzheimer's disease, but I think it can fast-forward someone towards it,' he said.
More research will need to be done to determine whether treating metabolic syndrome actually delays the onset of dementia or reduces the number of cases, Isaacson said. Researchers will also need to look into more populations to see if the results from South Korea can be broadly applied.
But the latest study does give hope that there are actions people can take to combat young-onset dementia, he said. 'Some people say young onset-dementia, you can't do anything about that –– it's preordained, but I don't agree with that. These lifestyle factors are nontrivial,' he added.
Lee believes people can influence their odds. 'My advice is to proactively manage metabolic health by maintaining a balanced diet, regular physical activity, and routine medical check-ups,' he said. 'Addressing metabolic syndrome early can substantially reduce the risk of dementia later in life.'
The conditions that make up metabolic syndrome may not seem immediately connected to dementia risk, but there are a few ways that vascular health can impact cognitive decline, Isaacson said.
Metabolic syndrome can lead to inflammation, and 'when someone has inflammation in the body and in the brain, it can fast-forward aging,' Isaacson said. 'And when you have inflammation in the brain, things don't work as well.'
Your blood vessels working efficiently is also important to cognitive health to keep enough oxygen flowing to the brain, he added.
And finally, he noted that metabolic syndrome may affect the brain's ability to metabolize energy, which may lead to cognitive impairment.
The different conditions that make up metabolic syndrome tend to happen together because they have similar causes and impact one another, he added.
'When a person is physically inactive and has an unhealthy diet … and someone is not sleeping and just kind of burning the candle at both ends … poor activity, low exercise: These are the medical or clinical manifestations of that sort of thing,' Isaacson said. 'That's why these risk factors often flock together — because they really are interrelated.'
Because both genetic and lifestyle factors contribute to dementia cases, some people can do everything their doctor suggests and still get dementia, Isaacson said. But making healthy lifestyle changes and addressing metabolic syndrome may still prevent or delay dementia in many people, he added.
Treatment for metabolic syndrome, which can also increase the risk of diabetes and cardiovascular conditions, starts with lifestyle changes, said Dr. Pam Taub, a preventive cardiologist and professor of medicine at the University of California San Diego. She was not involved in the research.
'In general, the lifestyle recommendations that we recommend are really having a balanced Mediterranean diet, a diet that is balanced in terms of proteins, carbohydrates, and fiber, and also limiting the amount of calorie intake,' she added.
Some of Taub's research into metabolic syndrome shows that time-restricted eating can help manage the conditions, she said.
Maintaining regular physical activity is key, though the amount and the proportion of strength, cardio and flexibility training may be specific to you and discussed with your doctor, she said. Getting enough sleep and handling stress are also essential in managing almost every chronic condition, she added.
'Of course, we can't control the stress that's thrown at us, but it's how we modulate our response that is important,' Taub said.
But lifestyle changes alone may not solve the problem completely, she said. Your doctor may recommend medications to help with blood pressure, blood sugar, insulin resistance, lipid lowering and weight management.
'It's really not one or the other,' Taub said. 'You have to synergize both lifestyle and pharmacology.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 days ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
Yahoo
2 days ago
- Yahoo
Three factors will stall dementia and the aging process, according to new U.S. study
By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent compared to 2020, when approximately 597,300 Canadians were living with dementia, according to the Alzheimer's Society of Canada. Dementia describes the decline of mental ability, while Alzheimer's Disease is the medical term for the brain disease that commonly causes dementia. Researchers are now saying certain lifestyle changes can stave off mental decline. A new U.S. study sets out what Alzheimer's researchers are calling the strongest evidence yet regarding what is involved in slowing the aging process and improving cognition. It comes down to three key factors: a diet heavy on leafy greens, berries and grains, regular moderate exercise and ongoing social interaction. Regular cardiovascular monitoring is also a factor. Jessica Langbaum, senior director of research strategy at the Banner Alzheimer's Institute in Phoenix was not involved directly in the research but she presented the findings at an annual conference of experts in Toronto on Wednesday. The Alzheimer's Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science and clinical practice. This year's gathering brought together 8,000 scientists and clinicians from all over the world, with the goal of improving diagnosis, risk reduction and treatment. The study pulled together diet, exercise and socialization in one substantial, structured study of 2,100 people in their 60s and 70s at risk of developing dementia, showing that bad habits 'can really slow down memory and thinking' in adults at risk for cognitive impairment and dementia, Langbaum told the PBS New Hour in an interview on Wednesday evening. The subjects who participated in the study changed their habits, shifting from a sedentary lifestyle to an active one and improving their diet over a two-year period, resulting in cognitive function scores on par with people one or two years younger. That might not sound like much, but Langbaum says the results are significant evidence that change can occur without medication. 'And so, it's showing that we can change the trajectory of aging,' she said. There were two groups in the study. In one, lifestyle changes were structurally prescribed. In the other, the changes were self-directed. The results for the prescribed group were much better, but Langbaum says both groups showed improvement. The biggest challenge that study participants faced was sustaining a new exercise regime. Langbaum recommends people find something that they enjoy doing. 'If (you're) frustrated by it, (you're) just going to give up. But do something that you enjoy. Better yet, do it with somebody else or others around you because socialization is key, and lastly, something that you can adhere to, if you can schedule it. It's something that you can stay committed to.' Regarding nutrition she notes: 'We say what's good for the heart is good for the brain, so a nice balanced … nutritious diet with … those leafy greens, low in saturated fats, all of those things.' The American Alzheimer's Association spent close to US$50 million on the study. The National Institutes of Health spent even more to ensure many of the participants underwent brain scans, blood tests and sleep studies aimed at provide additional information down the road. Meanwhile, Langbaum expresses concern that structured intervention may not be sustainable in most communities. 'I think that's really the next stage of the research is, how do we make this scalable in communities so that people can implement these things into their daily lives?' The American Alzheimer's Association is planning to spend another US$40 million on implementing the lessons of the study. Langbaum says that will come with a change in the mindsets of doctors. They 'should be treating lifestyle interventions as they would a drug,' she told NPR. That would mean prescribing improved exercise and eating regimens and getting insurers to cover those prescriptions, she added. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Newsweek
2 days ago
- Newsweek
A Doctor's Plea From a Nation Asleep on Brain Disease
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.
